keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg seroconversion

keyword
https://www.readbyqxmd.com/read/28884879/analysis-of-hbsag-using-high-sensitivity-hbsag-assays-in-hepatitis-b-virus-carriers-in-whom-hbsag-seroclearance-was-confirmed-by-conventional-assays
#1
Itaru Ozeki, Tomoaki Nakajima, Hirokazu Suii, Ryoji Tatsumi, Masakatsu Yamaguchi, Mutsuumi Kimura, Tomohiro Arakawa, Yasuaki Kuwata, Takumi Ohmura, Shuhei Hige, Yoshiyasu Karino, Joji Toyota
AIM: We investigated the utility of high-sensitivity hepatitis B surface antigen (HBsAg) assays compared with conventional HBsAg assays. METHODS: Using serum samples from 114 hepatitis B virus (HBV) carriers in whom HBsAg seroclearance was confirmed by conventional HBsAg assays (cutoff value, 0.05 IU/mL), the amount of HBsAg was re-examined by high-sensitivity HBsAg assays (cutoff value, 0.005 IU/mL). Cases negative for HBsAg in both assays were defined as consistent cases, and cases positive for HBsAg in the high-sensitivity HBsAg assay only were defined as discrepant cases...
September 8, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28880694/pronounced-decline-of-serum-hbsag-in-chronic-hepatitis-b-patients-with-long-term-effective-nucleos-t-ide-analogs-therapy
#2
Meng-Lan Wang, En-Qiang Chen, Chuan-Min Tao, Tao-You Zhou, Juan Liao, Dong-Mei Zhang, Juan Wang, Hong Tang
AIMS: This study aims to investigate the kinetics of serum HBsAg levels in chronic hepatitis B patients with long-term nucleos(t)ide analogs (NAs) therapy. METHODS: This was a retrospective clinical study. Serum HBsAg in serial samples of 94 patients, who received at least 8 years of NAs therapy, were measured using Elecsys(®) HBsAg II Quant Assay. RESULTS: In this cohort, serum HBsAg levels reduced from 3.80 log10 IU/mL at baseline to 2...
September 7, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28875955/efficacy-of-real-world-entecavir-therapy-in-treatment-na%C3%A3-ve-chronic-hepatitis-b-patients
#3
Yan-Di Xie, Hui Ma, Bo Feng, Lai Wei
Background: Entecavir (ETV) has been shown to be effective in randomized controlled trials in highly selected patients with hepatitis B virus (HBV) infection. This study aimed to evaluate the efficacy of ETV in chronic hepatitis B (CHB) patients in the real-world setting. Methods: A total of 233 treatment-naïve, CHB patients who received at least 12 months of ETV treatment were included in this retrospective study. Rates of virological response (VR), hepatitis B s antigen (HBsAg) loss, hepatitis B e antigen (HBeAg) clearance/seroconversion, virological breakthrough, cirrhosis, and hepatocellular carcinoma were evaluated...
September 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28869890/development-of-anti-hepatitis-b-surface-hbs-antibodies-after-hbs-antigen-loss-in-hiv-hepatitis-b-virus-co-infected-patients
#4
Anders Boyd, Laetitia Canini, Joël Gozlan, Caroline Lascoux-Combe, Patrick Miailhes, Laurent Fonquernie, Pierre-Marie Girard, Karine Lacombe
BACKGROUND: Hepatitis B surface antigen (HBsAg)-seroconversion, or loss of HBsAg and acquisition of anti-hepatitis B surface (HBs) antibodies, defines functional cure of chronic hepatitis B virus (HBV) infection. After HBsAg-loss, little is known regarding the development of anti-HBs antibodies and even less so in individuals co-infected with HIV. OBJECTIVES: To determine anti-HBs antibody kinetics after HBsAg-loss and explore determinants of HBsAg-seroconversion in HIV-HBV co-infected patients...
August 25, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28836955/prevalence-of-hepatitis-b-in-people-living-with-hiv-aids-in-latin-america-and-the-caribbean-a-systematic-review-and-meta-analysis
#5
Fatima Mitiko Tengan, Edson Abdala, Marisa Nascimento, Wanderley Marques Bernardo, Antonio Alci Barone
BACKGROUND: Hepatitis B virus (HBV) infection is a major cause of chronic liver disease worldwide. In immunocompromised patients, the chronicity rates of HBV infection are higher, but the rates of hepatitis Be antigen (HBeAg) and HBsAg loss and seroconversion to anti-HBe and anti-HBs are lower than those in immunocompetent subjects. This study aimed to evaluate articles on the prevalence of HBsAg in people living with human immunodeficiency virus (HIV) /AIDS (PLWHA) in Latin America and the Caribbean (LAC)...
August 24, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28827021/toward-cure-chronic-hepatitis-b-infection-and-hepatocellular-carcinoma-prevention-lessons-learned-from-nucleos-t-ide-analogues-therapy
#6
REVIEW
Soheil Tavakolpour, Hajar Sadat Mirsafaei, Somayeh Elkaei Behjati, Mojtaba Ghasemiadl, Meisam Akhlaghdoust, Shahnaz Sali
Nucleos(t)ide analogues (NAs) could successfully suppress hepatitis B virus (HBV) replication in patients with chronic hepatitis B (CHB). However, due to probable development of drug resistance or low/delayed response, these treatments may not be satisfactory. In addition to the HBV DNA polymerase inhibiting activity, these drugs could lead to changes in cytokines profiles. It is important to monitor these changes so that they could be used as target of treatment. Evaluating the previously reported immune responses due to NAs treatments, it was concluded that interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin-4 (IL-4), and IL-12 increase after the treatment...
August 5, 2017: Immunology Letters
https://www.readbyqxmd.com/read/28820727/sustained-off-treatment-response-after-discontinuation-of-long-term-nucleos-t-ide-analogue-treatment-in-hbeag-seronegative-hepatitis-b-a-case-series
#7
Marion Muche, Ulrike Meyer, Britta Siegmund, Rajan Somasundaram, Hans-Joerg Epple
International guidelines recommend lifelong nucleos(t)ide analogue (NA) treatment in individuals with chronic hepatitis B (CHB) infection who are hepatitis B e antigen (HBeAg) seronegative, because hepatitis B surface antigen (HBsAg) seroconversion is rarely achieved. However, after terminating therapy, sustained responses and HBsAg loss have been observed. Clinical characteristics identifying persons with favorable outcomes after discontinuing NA therapy have not yet been defined. This case series describes outcomes of 6 individuals with HBeAg-seronegative CHB infection without cirrhosis and low plasma levels of HBsAg who discontinued long-term NA treatment...
July 2017: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/28802168/impact-of-hepatitis-b-vaccination-on-hbsag-kinetics-interferon-inducible-protein-10-level-and-recurrence-of-viremia
#8
Amr Shaaban Hanafy
BACKGROUND AND AIMS: Persistent HBs antigenemia >1000IU/ml has a possibility of viral reactivation and HCC in 8%, so we investigated the effect of HBV vaccine on HBsAg, IP-10, and recurrence of viremia. METHODS: Group I: inactive carriers(n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 1year after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or3years after DNA disappearance in HBeAg negativepatients (n=60). All showed persistent HBs antigenemia...
August 9, 2017: Cytokine
https://www.readbyqxmd.com/read/28757048/a-long-term-multicenter-study-entecavir-versus-tenofovir-in-treatment-of-nucleos-t-ide-analogue-naive-chronic-hepatitis-b-patients
#9
Bircan Kayaaslan, Esragul Akinci, Alpay Ari, Zeliha Kocak Tufan, Saygın Nayman Alpat, Ozgur Gunal, Selma Tosun, Rahmet Guner, Fehmi Tabak
BACKGROUND: Entecavir (ETV) and tenofovir disoproxil fumarat (TDF) are the two first-line therapies recommended in the treatment of chronic hepatitis B because of having potent antiviral effect and high genetic barriers against resistance. We aimed to compare efficacy of these drugs and to evaluate predictors of viral suppression. METHODS: This multicenter retrospective study was conducted in nucleos(t)ide analogue-naive chronic hepatitis B (CHB) patients from different 6 centers...
July 27, 2017: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/28724049/hepatitis-b-status-in-hemodialysis-patients
#10
Maia Nogueira Crown Guimarães, Tila Facincani, Sigrid De Sousa Dos Santos
BACKGROUND: Patients on chronic dialysis present a high prevalence of hepatitis B virus infection. Despite infection-control practices, surveillance of serological markers, and hepatitis B vaccination, there are still outbreaks of the disease in dialysis centers. OBJECTIVE: This study aims to assess the serologic and vaccination status for hepatitis B in hemodialysis patients. METHODS: This cross-sectional study assessed serologic markers and hepatitis B vaccination status of chronic kidney disease patients on regular dialysis program in São Carlos, SP, Brazil...
July 13, 2017: Arquivos de Gastroenterologia
https://www.readbyqxmd.com/read/28687350/clinical-response-to-long-term-tenofovir-monotherapy-in-korean-chronic-hepatitis-b-patients
#11
Eun-Hyung Yoo, Hyun-Jung Cho
BACKGROUND: Tenofovir disoproxil fumarate (TDF) is a potent nucleotide analogue recommended as first-line monotherapy for chronic hepatitis B (CHB). We investigated the clinical response to TDF monotherapy in Korean CHB patients. METHODS: A total of 90 CHB patients [55 hepatitis B e antigen (HBeAg)-positive and 35 HBeAg-negative] who received TDF monotherapy for >2year, were enrolled. Quantitative hepatitis B surface antigen (qHBsAg) levels, serum alanine aminotransferase (ALT), HBeAg, anti-HBe and HBV DNA levels were measured during treatment...
August 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/28639033/functional-restoration-of-cd56-bright-nk-cells-facilitates-immune-control-via-il-15-and-nkg2d-in-patients-under-antiviral-treatment-for-chronic-hepatitis-b
#12
Tao Chen, Lin Zhu, Aichao Shi, Lin Ding, Xiaoping Zhang, Zhenmin Tan, Wei Guo, Weiming Yan, Meifang Han, Jidong Jia, Xiaoping Luo, Detlef Schuppan, Qin Ning
BACKGROUND AND AIMS: Hepatitis B virus (HBV) is intrinsically immunogenic, with long-lasting immune control in many patients. However, the mechanisms and key cell types underlying effective immune control are incompletely understood. METHODS: We studied the restoration of natural killer (NK) cell numbers and function post antiviral treatment in 52 hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients who received telbivudine (LdT) for 48 weeks...
June 20, 2017: Hepatology International
https://www.readbyqxmd.com/read/28636622/inhibition-of-hepatitis-b-viral-entry-by-nucleic-acid-polymers-in-heparg-cells-and-primary-human-hepatocytes
#13
Clément Guillot, Nora Martel, Françoise Berby, Isabelle Bordes, Olivier Hantz, Matthieu Blanchet, Camille Sureau, Andrew Vaillant, Isabelle Chemin
Hepatitis B virus (HBV) infection remains a major public health concern worldwide with 240 million individuals chronically infected and at risk of developing cirrhosis and hepatocellular carcinoma. Current treatments rarely cure chronic hepatitis B infection, highlighting the need for new anti-HBV drugs. Nucleic acid polymers (NAPs) are phosphorothioated oligonucleotides that have demonstrated a great potential to inhibit infection with several viruses. In chronically infected human patients, NAPs administration lead to a decline of blood HBsAg and HBV DNA and to HBsAg seroconversion, the expected signs of functional cure...
2017: PloS One
https://www.readbyqxmd.com/read/28611343/hbsag-clearance-in-chronic-hepatitis-b-patients-with-add-on-pegylated-interferon-alfa-2a-to-ongoing-tenofovir-treatment-a-randomized-controlled-study
#14
Hamad Al Ashgar, Musthafa C Peedikayil, Mohammed Al Quaiz, Fahad Al Sohaibani, Abdulrahman Al Fadda, Mohammed Q Khan, Einar Thoralsson, Sahar Al Thawadi, Ahmed Al Jedai, Khalid Al Kahtani
BACKGROUND/AIMS: The ideal end point of treatment for chronic hepatitis B virus (HBV) infection is sustained off-therapy hepatitis B surface antigen (HBsAg) loss with or even without seroconversion to anti-HBs. We investigated the role of adding PEGylated interferon (PEG IFN) to ongoing tenofovir treatment in chronic HBV patients for achieving HBsAg clearance. PATIENTS AND METHODS: In this randomized controlled trial, chronic HBV patients who have been receiving tenofovir for >6 months with HBV viral load <2000 IU/ml were randomized into two groups...
May 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28581644/hepatitis-b-surface-antigen-loss-and-sustained-viral-suppression-in-asian-chronic-hepatitis-b-patients-a-community-based-real-world-study
#15
Robert J Wong, My T Nguyen, Huy N Trinh, Chuck Chan, Andrew Huynh, My Tops Ly, Huy A Nguyen, Khanh K Nguyen, Sharon Torres, Jenny Yang, Benny Liu, Ruel T Garcia, Taft Bhuket, Rachel Baden, Brian Levitt, Eduardo da Silveira, Robert G Gish
Community-based real-world outcomes on effectiveness of antiviral therapies for chronic hepatitis B virus (CHB) in Asians are limited. Whether hepatitis B surface antigen (HBsAg) loss correlates with undetectable virus and alanine aminotransferase (ALT) normalization on treatment or what predicts risk of seroreversion or detectable virus after stopping therapy is unclear. We aim to evaluate rates and predictors of HBsAg loss, seroconversion, ALT normalization and undetectable HBV DNA, including HBsAg seroreversion or re-emergence of HBV DNA among Asian CHB patients...
June 5, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28554002/retrospective-analysis-of-hepatitis-b-virus-chronic-infection-in-247-patients-clinical-stages-response-to-treatment-and-poor-prognostic-factors
#16
Marlone Cunha-Silva, Fábio R T Marinho, Paulo F Oliveira, Tirzah M Lopes, Tiago Sevá-Pereira, Sonia L S Lorena, Jazon R S Almeida
BACKGROUND: Chronic hepatitis B is a major cause of cirrhosis, and the natural history of the disease has several clinical stages that should be thoroughly understood for the implementation of proper treatment. Nonetheless, curing the disease with antiviral treatment remains a challenge. AIMS: To describe the clinical course, response to treatment, and poor prognostic factors in 247 hepatitis B virus chronic infection patients treated in a tertiary hospital in Brazil...
July 2017: Brazilian Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28500636/immune-correlates-of-hepatitis-b-surface-antigen-spontaneous-seroconversion-in-hepatitis-b-e-antigen-negative-chronic-hepatitis-b-patients
#17
Ashish Kumar Vyas, Barjesh Chander Sharma, Shiv Kumar Sarin, Nirupma Trehanpati
BACKGROUND: Hepatitis B surface antigen (HBsAg) seroconversion in HBeAg-ve chronic hepatitis B (CHB) infection is rare, possibly due to poor antigen processing and impaired humoral response. We investigated the role of dendritic cells (DCs), T follicular helper (TFH) cells and plasma B cells in seroconversion. METHODS: HBeAg-ve (n=135) CHB patients with raised ALT at baseline were followed-up. Patients undergoing HBsAg sero-conversion (Gr. I, n=11) were compared with non-converters with low (Gr...
May 13, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28489180/does-infection-by-the-hepatitis-c-virus-decrease-the-response-of-immunization-against-the-hepatitis-b-virus-in-individuals-undergoing-dialysis
#18
Tarcila Maria Bonfim Ferreira, Tácio Giordano Santana Guimarães, Andrea Martins Melo Fontenele, Natalino Salgado, Adalgisa de Souza Paiva Ferreira, Alessandra Porto de Macedo Costa
Introduction: Vaccination is the most effective tool in preventing transmission of Hepatitis B Virus (HBV). The patient with chronic kidney disease (CKD) on dialysis appear to be at greater risk of becoming infected with this virus and does not show the same vaccine response when compared to patients without uremia. Objectives: To evaluate the results related to the HBV vaccine and identify factors associated with the response in patients with CKD on hemodialysis...
April 27, 2017: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/28480195/alpha-interferon-treatment-in-hepatitis-b
#19
REVIEW
Aaron Shu Jeng Woo, Raymond Kwok, Taufique Ahmed
Pegylated interferon-α (PEG-IFN-α) is a first line option in the treatment of chronic hepatitis B. Compared with nucleos(t)ide analogues (NAs), therapy with PEG-IFN-α has the advantages of finite treatment duration and higher rates of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) seroconversion, but the disadvantage of greater adverse effects. Choosing PEG-IFN-α requires careful evaluation of the likelihood of achieving a sustained off-treatment response. Sustained off-treatment response with PEG-IFN-α can be predicted by baseline factors in HBeAg positive disease...
April 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28440484/expression-of-programmed-cell-death1-in-t-follicular-helper-cells-is-regulated-by-prostaglandin-e2-secreted-by-hbv-infected-hepg2-2-1-5-cells
#20
Zhefeng Sui, Ying Shi, Zhiling Gao, Deguang Yang, Zhihao Wang
The present study aimed to investigate the distribution of T follicular helper (Tfh)-cell subsets in patients with hepatitis B virus (HBV) and determine the underlying mechanism of HBV regulation of Tfh cells. The frequency of peripheral blood Tfh subsets was analyzed using flow cytometry. The expression level of programmed cell death‑1 (PD‑1) and prostaglandin E2 (PGE2) was quantified using reverse transcription‑quantitative polymerase chain reaction and western blotting. The PGE2 level in culture supernatant was detected using enzyme‑linked immunosorbent assay...
June 2017: Molecular Medicine Reports
keyword
keyword
31626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"